1 and identify the recommended phase 2 dose of guadecitabine.

2 l patients who received at least one dose of guadecitabine.

3 s-treated) who received at least one dose of guadecitabine.

4                                              Guadecitabine 60 mg/m(2) daily x 5 is the recommended ph

5      We also assigned additional patients to guadecitabine 60 mg/m(2) in a 10-day schedule in a 28-da

6 opulation is ongoing (NCT02348489) to assess guadecitabine 60 mg/m(2) in a 5-day schedule versus stan

7 ter algorithm (for dynamic randomisation) to guadecitabine 60 or 90 mg/m(2) on days 1-5 (5-day schedu

8                                              Guadecitabine, a next-generation hypomethylating drug, h

9  achieved a composite complete response with guadecitabine at all drug doses and schedules investigat

10 ive was to assess safety and tolerability of guadecitabine, determine the maximum tolerated and biolo

11 n was used in which we treated patients with guadecitabine doses of 3-125 mg/m(2) in separate dose-es

12 domly assigned (1:1) to receive subcutaneous guadecitabine, either once-daily for 5 consecutive days

13       A phase 1 study established 60 mg/m(2) guadecitabine for 5 days as an effective treatment sched

14                                              Guadecitabine given subcutaneously at 60 mg/m(2) daily x

15 , randomised, open-label, phase 1/2 study of guadecitabine in cohorts of patients with treatment-naiv

16 y and activity of two doses and schedules of guadecitabine in older (>/=65 years) patients with treat

17 nd clinical activity of subcutaneously given guadecitabine in patients with acute myeloid leukaemia o

18 tin plus the DNA methyltransferase inhibitor guadecitabine or a standard-of-care chemotherapy regimen

19                              The recommended guadecitabine regimen for this population is 60 mg/m(2)

20                                              Guadecitabine (SGI-110) is a novel hypomethylating dinuc

21 rs that were hypomethylated significantly by guadecitabine, with 1,659 genes differentially expressed